Table 1.
Baseline demographics and disease characteristics
| Characteristic | ADA 40 mg every week up to week 52 (n = 15) | ADA 40 mg every week after week 52 (n = 8) | ADA 80 mg every other week after week 52 (n = 6) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 13 (87) | 7 (88) | 5 (83) |
| Female | 2 (13) | 1 (13) | 1 (17) |
| Age, years | 42.1 (6.94) | 42.1 (7.02) | 40.7 (7.15) |
| Median age (range), years | 44 (26–52) | 44 (26–48) | 40 (31–52) |
| Median BMI (range), kg/m2 | 26.5 (18.1–50.6) | 24.4 (18.1–40.6) | 27.2 (21.8–33.7) |
| Hurley stage, n (%) | |||
| II | 9 (60) | 3 (38) | 5 (83) |
| III | 6 (40) | 5 (63) | 1 (17) |
| HS duration, years | 14.1 (10.58) | 16.2 (12.67) | 13.3 (7.02) |
| C‐reactive protein, mg/L | 8.3 (11.81) | 12.1 (15.29) | 3.6 (3.66) |
| Prior HS systemic medication, n (%) | 9 (60) | 5 (63) | 3 (50) |
| Prior HS surgery, n (%) | 6 (40) | 3 (38) | 3 (50) |
| HS lesion count | |||
| Abscess | 2.8 (3.43) | 3.5 (3.96) | 2.3 (2.88) |
| Draining fistula | 3.0 (3.87) | 3.0 (2.33) | 3.5 (5.68) |
| Non‐draining fistula | 7.5 (6.42) | 6.4 (5.97) | 10.2 (6.62) |
| Inflammatory nodule | 7.5 (6.08) | 4.4 (2.77) | 9.3 (6.06) |
| Hypertrophic scar | 8.1 (9.39) | 9.1 (11.31) | 6.3 (7.87) |
| Modified Sartorius score | 137.3 (59.21) | 125.9 (53.72) | 157.0 (70.44) |
| NRS of skin pain due to HS at worst among patients with baseline NRS of ≥3 | 4.6 (0.60) | 4.4 (0.55) | 5.2 (0.51) |
Data are presented as mean (standard deviation), unless otherwise noted. ADA, adalimumab; BMI, body mass index; DLQI, Dermatology Life Quality Index; HS, hidradenitis suppurativa; NRS, numeric rating scale.